MedTrace Logo

Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus

NCT01154348 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2018-04-27

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and pharmacokinetics of double-blind S-707106 alone and in combination with open-label metformin in patients with type 2 diabetes mellitus

Conditions

Interventions

DRUG

S-707106

Tablet, taken once daily with morning meal

DRUG

Placebo

Placebo tablet, taken once daily with morning meal

DRUG

Metformin, S-707106 plus metformin

Metformin twice daily maintenance, S-707106 tablet taken once daily with morning meal with metformin dosed twice daily

DRUG

Metformin, placebo plus metformin

Metformin twice daily maintenance, placebo tablet taken once daily with morning meal with metformin twice daily

Sponsors & Collaborators

  • Shionogi

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2010-11-30
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01154348 on ClinicalTrials.gov